Study of Continuous OSI-906 Dosing

ABSTRACT: Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.

DISEASE(S): Ovarian Cancer,Advanced Solid Tumors,Non-small Cell Lung Cancer,Colorectal Cancer,Advanced Cancer,Breast Cancer

PROVIDER: 2043046 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR